New findings by scientists at the University could help to predict how people with the most common form of leukaemia will respond to chemotherapy. The findings will help doctors decide which type of treatment to give patients.
The researchers, who were funded by the blood cancer research charity Bloodwise, analysed DNA samples from over 600 people with chronic lymphocytic leukaemia (CLL) treated on clinical trials with chemotherapy, or chemotherapy combined with immunotherapy. They identified a ‘genetic signature’, found in one in five patients, linked to considerably longer survival times.
Read the full story on our news pages.
